40 Participants Needed

Multi-disciplinary Care for Brain Cancer

AA
Overseen ByAlissa A Thomas, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Vermont Medical Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment 'Multi-disciplinary Care for Brain Cancer'?

Research shows that a multidisciplinary approach, where multiple specialists work together, improves patient outcomes in various cancers, including brain cancer. This approach allows for comprehensive care and better coordination, which can lead to improved quality of life and treatment success.12345

Is multi-disciplinary care generally safe for humans?

Research shows that involving a pharmacist in a multi-disciplinary care team can help prevent adverse drug events (harmful reactions to medications) in adults, suggesting that this approach is generally safe and can reduce medication-related risks.678910

How is the treatment 'Intensive Multi-disciplinary Care' for brain cancer different from other treatments?

Intensive Multi-disciplinary Care for brain cancer is unique because it involves a team of specialists from different fields working together to create a comprehensive treatment plan, allowing patients to see multiple providers on the same day. This approach aims to improve coordination and decision-making, which can lead to better patient outcomes compared to traditional care where specialists work independently.13111213

What is the purpose of this trial?

This is a health services intervention study aimed at understanding the impact of intensive multi-disciplinary care compared with standard care on patient-reported symptom outcomes and prognostic awareness in patients with brain metastases.

Eligibility Criteria

This clinical trial is for patients with brain metastases, which are cancerous tumors that have spread to the brain. Participants should be those who require a new approach to care and are currently receiving standard treatment.

Inclusion Criteria

I can complete questionnaires in English.
I have been newly diagnosed with brain metastases from a solid tumor.
I can accurately report my own health data.
See 1 more

Exclusion Criteria

Pregnant patients are not eligible.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either standard of care or intensive multi-disciplinary care for brain metastases

6-12 months

Follow-up

Participants are monitored for symptom burden, feasibility, and survival outcomes

6-12 months

Treatment Details

Interventions

  • Health Services Intervention
Trial Overview The study is testing whether an intensive multi-disciplinary care approach can improve patient-reported symptoms and awareness of their prognosis compared to standard care in individuals with brain metastases.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Multidisciplinary CareExperimental Treatment1 Intervention
Group II: Standard of CareActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Vermont Medical Center

Lead Sponsor

Trials
46
Recruited
25,900+

Findings from Research

The implementation of a multidisciplinary clinic (MDC) for neuro-oncology care improved overall survival for patients with CNS metastatic disease, with median survival increasing from 248 days before MDC to 315 days after (P<0.027).
The MDC also enhanced follow-up consistency across different specialties, addressing discrepancies in follow-up imaging that existed prior to its implementation.
Neuro-oncology Multidisciplinary Clinic and Improvements in Patient Outcome.Kubicek, GJ., Yocum, N., Thomas, C., et al.[2021]
The guidelines for managing adults with malignant cerebral glioma were developed by a diverse working group, ensuring that both medical effectiveness and patient perspectives were considered, which can lead to improved patient care.
The document outlines key stages of care, from diagnosis to treatment planning and follow-up, and includes an audit package for treatment centers to evaluate their practices against these standards, highlighting the importance of continuous improvement in patient management.
Good practice in the management of adults with malignant cerebral glioma: clinical guidelines. Working Group, Royal College of Physicians.Davies, E., Hopkins, A.[2019]
The reorganization of the Belgian oncology care system has led to the implementation of standardized care programs and the establishment of multidisciplinary oncology consultations (MOC), which are essential for developing comprehensive treatment plans for cancer patients.
The success of the MOC approach is driven by both legal requirements for reimbursement and the medical community's commitment to improving patient outcomes through collaboration among specialists.
How to implement the multidisciplinary approach in prostate cancer management: the Belgian model.Van Belle, S.[2022]

References

Neuro-oncology Multidisciplinary Clinic and Improvements in Patient Outcome. [2021]
Good practice in the management of adults with malignant cerebral glioma: clinical guidelines. Working Group, Royal College of Physicians. [2019]
How to implement the multidisciplinary approach in prostate cancer management: the Belgian model. [2022]
Team functioning across different tumour types: Insights from a Swiss cancer center using qualitative and quantitative methods. [2022]
[Multidisciplinary approach in breast cancer care]. [2009]
Adverse drug events resulting in admission to the intensive care unit in oncology patients: Incidence, characteristics and associated cost. [2013]
Intervention of pharmacist included in multidisciplinary team to reduce adverse drug event: a qualitative systematic review. [2023]
Targeting outpatient drug safety: recommendations of the Dutch HARM-Wrestling Task Force. [2021]
Adverse events in neurosurgery and their relationship to quality improvement. [2015]
CareTrack Kids-part 3. Adverse events in children's healthcare in Australia: study protocol for a retrospective medical record review. [2019]
11.United Statespubmed.ncbi.nlm.nih.gov
The role of tumor board conferences in neuro-oncology: a nationwide provider survey. [2018]
Improvements in quality of care resulting from a formal multidisciplinary tumour clinic in the management of high-grade glioma. [2022]
Editorial: Brain tumour treatment: the concept of inter- and multidisciplinary treatment. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security